Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001140361-17-040967
Filing Date
2017-11-03
Accepted
2017-11-03 16:16:34
Documents
83
Period of Report
2017-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q form10q.htm 10-Q 784170
2 EXHIBIT 31.1 ex31_1.htm EX-31.1 11431
3 EXHIBIT 31.2 ex31_2.htm EX-31.2 11187
4 EXHIBIT 32.1 ex32_1.htm EX-32.1 6570
5 EXHIBIT 32.2 ex32_2.htm EX-32.2 6549
  Complete submission text file 0001140361-17-040967.txt   6037336

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT rnn-20170930.xml EX-101.INS 1543881
7 XBRL TAXONOMY EXTENSION SCHEMA rnn-20170930.xsd EX-101.SCH 58994
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE rnn-20170930_cal.xml EX-101.CAL 50882
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE rnn-20170930_def.xml EX-101.DEF 179881
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE rnn-20170930_lab.xml EX-101.LAB 402838
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rnn-20170930_pre.xml EX-101.PRE 350152
Mailing Address 15245 SHADY GROVE ROAD, SUITE 455 ROCKVILLE MD 20850
Business Address 15245 SHADY GROVE ROAD, SUITE 455 ROCKVILLE MD 20850 2402685300
REXAHN PHARMACEUTICALS, INC. (Filer) CIK: 0001228627 (see all company filings)

EIN.: 113516358 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-34079 | Film No.: 171176603
SIC: 2834 Pharmaceutical Preparations